Skip to Content

Join the 'Nephropathic Cystinosis' group to help and get support from people like you.

Nephropathic Cystinosis News

FDA Approves Expanded Label for Procysbi to Treat Children Aged 2-6 Years With Nephropathic Cystinosis

Posted 20 Aug 2015 by

NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) – Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of Procysbi (cysteamine bitartrate) delayed-release capsules to treat children two to six years of age with nephropathic cystinosis. The approved supplement was based on efficacy and safety data from an ongoing ...

Ask a Question

Further Information

Related Condition Support Groups

Metabolic Disorder Including Congenital

Related Drug Support Groups

cysteamine, Cystagon, Procysbi